Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥75years with impaired performance status

Roberto Petrioli; Edoardo Francini; Franco Roviello; Daniele Marrelli; Salvatora Tindara Miano; Anna Ida Fiaschi; Letizia Laera; Marco Antonio Bellini; Giandomenico Roviello

doi:10.1016/j.jgo.2015.06.002

Back

Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥75years with impaired performance status

Journal article

Peer reviewed

Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥75years with impaired performance status

Roberto Petrioli, Edoardo Francini, Franco Roviello, Daniele Marrelli, Salvatora Tindara Miano, Anna Ida Fiaschi, Letizia Laera, Marco Antonio Bellini and Giandomenico Roviello

Journal of geriatric oncology, Vol.6(5), pp.380-386

09/2015

DOI: 10.1016/j.jgo.2015.06.002

PMID: 26228711

View Online

Abstract

To evaluate the efficacy and safety of FOLFOX-4 combination chemotherapy, followed by leucovorin (LV)/bolus and continuous infusion 5-fluorouracil (5-FU) as maintenance chemotherapy in elderly (≥75years) patients with advanced oesophagogastric cancer with impaired performance status (PS). Patients with a PS score >1 were included in this study. PS evaluations were performed by a geriatrician and two medical oncologists. FOLFOX-4 consisted of oxaliplatin concurrently with LV/bolus and continuous infusion 5-FU every 2weeks. After a maximum of six FOLFOX-4cycles, patients with no evidence of disease progression received maintenance treatment with LV/bolus and continuous infusion 5-FU every 2weeks until disease progression or unacceptable toxicity. Thirty-eight patients were enrolled in this study. Of these, 32 (84.2%) patients had a PS score of 2 and six (15.7%) patients had a PS score of 3. After completion of FOLFOX-4, 18 (47.3%) patients achieved a partial response and 14 (36.8%) patients had stable disease. Thirty-two patients (84.2%) received maintenance chemotherapy for a median of eight cycles (range one to 26cycles). The 6-month disease-control rate was 47.3% [95% confidence interval (CI) 30.9–64.1]. The median progression-free survival was 5.9months (95% CI 4.7–6.8) and the median overall survival was 9.6months (95% CI 8.1–11.7). Grade 3 neutropenia occurred in six patients (15.7%), and Grade 3 anaemia and thrombocytopenia occurred in two patients (5.2%). FOLFOX-4 followed by LV/bolus and continuous infusion 5-FU as maintenance chemotherapy seems to be an active and well-tolerated first-line treatment strategy for elderly patients with advanced oesophagogastric cancer and impaired PS.

Capecitabine

Elderly

FOLFOX

Gastric cancer

Performance status

Details

Title: Subtitle: Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥75years with impaired performance status
Creators: Roberto Petrioli - University of Siena
Edoardo Francini - Policlinico Umberto I
Franco Roviello - University of Siena
Daniele Marrelli - University of Siena
Salvatora Tindara Miano - University of Siena
Anna Ida Fiaschi - University of Siena
Letizia Laera - University of Siena
Marco Antonio Bellini - University of Siena
Giandomenico Roviello - University of Siena
Resource Type: Journal article
Publication Details: Journal of geriatric oncology, Vol.6(5), pp.380-386
DOI: 10.1016/j.jgo.2015.06.002
PMID: 26228711
ISSN: 1879-4068
eISSN: 1879-4076
Publisher: Elsevier Ltd; AMSTERDAM
Number of pages: 7
Language: English
Date published: 09/2015
Academic Unit: Internal Medicine
Record Identifier: 9985221245402771

Metrics

1 Record Views